Selena Fu, MD
Ophthalmology · Overland Park, KSNPI 1730296963
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,704 of the $5,236 with a category attached, or 89.8%. 13 manufacturers reported payments, led by AbbVie at 50.5% of the total.
Across 122 payments — averaging $42.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$949
- Galderma Laboratories, L.p.$594
- Revance Therapeutics, Inc.$337
- Sun Pharmaceutical Industries Inc.$266
- Alcon$259
- plus $187 from 7 others
What the payments were for
- Speaking & faculty fees$4689%
- Food & beverage$4,70490%
- Education$250%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $2,644 |
| Amgen(2 entities) | 13 | $949 |
| Galderma Laboratories, L.p. | 16 | $594 |
| Revance Therapeutics, Inc. | 9 | $337 |
| Sun Pharmaceutical Industries Inc. | 3 | $266 |
| Alcon | 2 | $259 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $51 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Lumenis, Inc | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Sight Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,236 in reported general payments places this provider in the 85th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $203 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Jason StahlOverland Park$10K
- Christopher KetchersideOverland Park$6K
- Timothy CavanaughOverland Park$5K
- Johann OhlyOverland Park$4K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.